Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "Head"

1973 News Found

DGCI gives a go-ahead for Phase III Sputnik Light trials
News | September 16, 2021

DGCI gives a go-ahead for Phase III Sputnik Light trials

The Lancet study said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines


World’s first clinical trial for a rare headache disorder
Biotech | September 15, 2021

World’s first clinical trial for a rare headache disorder

The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022


Bajaj Healthcare gets a go-ahead for 2-Deoxy-D-Glucose to treat Covid-19
Drug Approval | September 06, 2021

Bajaj Healthcare gets a go-ahead for 2-Deoxy-D-Glucose to treat Covid-19

Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence


Reliance Life Science gets go-ahead for Phase I clinical trial for Covid-19 vaccine
Drug Approval | September 04, 2021

Reliance Life Science gets go-ahead for Phase I clinical trial for Covid-19 vaccine

The trial will be conducted across eight sites in Maharashtra


India should focus on pharma intermediates self-sufficiency : A column by Dr. K. Nagaiah,Chief Scientist & Head - Centre for Natural Product and Traditional Knowledge, CSIR-IICT, Hyderabad
interviews | August 17, 2021

India should focus on pharma intermediates self-sufficiency : A column by Dr. K. Nagaiah,Chief Scientist & Head - Centre for Natural Product and Traditional Knowledge, CSIR-IICT, Hyderabad

India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers


Multiple catalysts ahead for Cadila Healthcare: HDFC Securities
News | May 31, 2021

Multiple catalysts ahead for Cadila Healthcare: HDFC Securities

Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.


Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke
Clinical Trials | February 07, 2026

Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke

These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke


GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease
News | February 07, 2026

GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease

Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype


Revvity posts higher Q4 earnings, lifts 2026 outlook as diagnostics strength offsets margin pressure
News | February 05, 2026

Revvity posts higher Q4 earnings, lifts 2026 outlook as diagnostics strength offsets margin pressure

Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come


Novo Nordisk weathers pricing pressure, bets big on oral Wegovy
News | February 05, 2026

Novo Nordisk weathers pricing pressure, bets big on oral Wegovy

Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates